ImmunoCellular Therapeutics (IMUC) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	IMUC
Entity Registrant Name	ImmunoCellular Therapeutics, Ltd.
Entity Central Index Key	822411
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		90,254,823

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$34,771,179	$23,222,296
Other assets	1,610,391	1,219,873
Total current assets	36,381,570	24,442,169
Property and equipment, net	42,430	47,365
Deferred financing costs		105,563
Other assets	553,805	583,464
Total assets	36,977,805	25,178,561
Current liabilities:
Accounts payable	492,615	322,002
Accrued compensation and benefits	147,576	334,527
Accrued liabilities	846,222	632,670
Total current liabilities	1,486,413	1,289,199
Warrant liability	3,122,077	597,719
Commitments and contingencies (Note 5)
Shareholders’ equity:
Common stock, $0.0001 par value; 149,000,000 shares authorized; 90,254,823 and 63,604,823 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	9,025	6,360
Additional paid-in capital	95,132,062	84,632,209
Accumulated deficit	-62,771,772	-61,346,926
Total shareholders’ equity	32,369,315	23,291,643
Total liabilities and shareholders’ equity	$36,977,805	$25,178,561

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	149,000,000	149,000,000
Common stock, shares issued	90,254,823	63,604,823
Common stock, shares outstanding	90,254,823	63,604,823

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Expenses:
Research and development	$1,998,619	$1,699,760
Stock based compensation	205,829	184,102
General and administrative	896,672	865,402
Total expenses	3,101,120	2,749,264
Loss before other income (expense) and income taxes	-3,101,120	-2,749,264
Interest income	3,257	3,354
Financing expense	-88,939
Change in fair value of warrant liability	1,761,956	-416,067
Loss before income taxes	-1,424,846	-3,161,977
Net loss	($1,424,846)	($3,161,977)
Net loss per share, basic and diluted:	($0.02)	($0.05)
Weighted average number of shares basic and diluted:	77,818,157	57,552,664

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited) (USD $)	Total	Common Stock and Warrants Issued for Cash 0.60 Per Share	Common Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital	Accumulated Deficit
				Common Stock and Warrants Issued for Cash 0.60 Per Share		Common Stock and Warrants Issued for Cash 0.60 Per Share
Beginning Balance at Dec. 31, 2014	$23,291,643		$6,360		$84,632,209		($61,346,926)
Balance, shares at Dec. 31, 2014			63,604,823
Common stock and warrants issued for cash, net of offering costs		10,296,689		2,665		10,294,024
Common stock and warrants issued for cash, net of offering costs, shares				26,650,000
Stock based compensation	205,829				205,829
Net loss	-1,424,846						-1,424,846
Ending Balance at Mar. 31, 2015	$32,369,315		$9,025		$95,132,062		($62,771,772)
Ending Balance, shares at Mar. 31, 2015			90,254,823

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) (USD $)	1 Months Ended
	Feb. 28, 2015
Common stock and warrants issued for cash per share	$0.60
Common Stock and Warrants Issued for Cash 0.60 Per Share
Common stock and warrants issued for cash per share	$0.60

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($1,424,846)	($3,161,977)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,693	12,634
(Gain) loss on disposal of assets		-4
Change in fair value of warrant liability	-1,761,956	416,067
Financing expense	88,939
Stock-based compensation	205,829	184,102
Changes in assets and liabilities:
Other assets	-360,859	30,927
Accounts payable	170,613	-290,665
Accrued compensation and benefits	-186,951	-203,464
Accrued liabilities	213,552	398,622
Net cash used in operating activities	-3,048,986	-2,613,758
Cash flows from investing activities:
Purchase of property and equipment	-1,758	-3,600
Proceeds from the sale of property and equipment		400
Net cash used in investing activities	-1,758	-3,200
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants from underwritten public offering, net of offering costs	14,599,627
Net cash provided by financing activities	14,599,627
Increase (decrease) in cash and cash equivalents	11,548,883	-2,616,958
Cash and cash equivalents, beginning of period	23,222,296	27,646,351
Cash and cash equivalents, end of period	$34,771,179	$25,029,393

Nature_of_Organization_Planned

Nature of Organization (Planned Principal Operations Have Not Commenced)	3 Months Ended
	Mar. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Organization (Planned Principal Operations Have Not Commenced)	1. Nature of Organization (Planned Principal Operations Have Not Commenced)
	ImmunoCellular Therapeutics, Ltd. (the Company) is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. These condensed consolidated financial statements include the Company’s wholly owned subsidiaries, ImmunoCellular Bermuda, Ltd. in Bermuda and ImmunoCellular Therapeutics (Ireland) Limited and ImmunoCellular Therapeutics (Europe) Limited in Ireland, that were formed during 2014.
	The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its vaccine product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, has recently begun start-up and planning activities for its Phase III trial. The Company has two other product candidates, ICT-140 and ICT-121, both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). Currently, the Company has suspended development of ICT-140 until the Company has secured a partner or sufficient financial resources to commence the ICT107 Phase III program.  Additionally, the Company has acquired the rights to technology for the development of certain stem cell immunotherapies for the treatment of cancer.  The Company has incurred operating losses and, as of March 31, 2015, the Company had an accumulated deficit of $62,771,772. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.
	The Company's activities are subject to significant risks and uncertainties, including the failure of any of the Company's product candidates to achieve clinical success or to obtain regulatory approval.  Additionally, it is possible that other companies with competing products and technology might obtain regulatory approval ahead of the Company.  The Company will need significant amounts of additional funding in order to complete the development of any of its product candidates and the availability and terms of such funding cannot be assured.
	Interim Results
	The accompanying condensed consolidated financial statements as of March 31, 2015 and for the three month periods ended March 31, 2015 and 2014 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2014 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC) on March 10, 2015.
	The condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended December 31, 2014. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Liquidity – As of March 31, 2015, the Company had working capital of $34,895,157, compared to working capital of $23,152,970 as of December 31, 2014. The estimated cost of completing the development of any of our current vaccine product candidates, including our stem cell immunotherapies, and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
	Principles of Consolidation - The condensed consolidated balance sheets include the accounts of the Company and its subsidiaries. The consolidated statements of operations include the Company’s accounts and the accounts of its subsidiaries from the date of acquisition. All intercompany transactions and balances have been eliminated in consolidation.
	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of March 31, 2015 and December 31, 2014, the Company had $33,431,067 and $10,427,810, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
	Stock Based Compensation – We have in effect an equity incentive plan under which stock options and awards have been granted to employees and non-employee members of the Board of Directors. We are required to estimate the fair value of share-based awards on the date of grant. The value of the award is principally recognized as expense ratably over the requisite service periods. We have estimated the fair value of stock options as of the date of grant using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. We evaluate the assumptions used to value stock options on a quarterly basis. The fair values generated by the Black-Scholes model may not be indicative of the actual fair values of our equity awards, as they do not consider other factors important to those awards to employees, such as continued employment and periodic vesting.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Three months			Three months
		Ended			Ended
		31-Mar-15			31-Mar-14
	Risk-free interest rate		1.87	%		2.23	%
	Expected dividend yield		None			None
	Expected life		7.1 Years			6.0Years
	Expected volatility		96.3	%		95.3	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the three months ended March 31, 2015 and 2014, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be zero.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises. As of March 31, 2015, the Company had 10,469,540 shares of authorized and unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of March 31, 2015 and December 31, 2014, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of March 31, 2015, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2010 for the state and December 31, 2011 for the federal taxing authority.
	During 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represented a gain for U.S. tax purposes and were offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a larger portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.
	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
	The following critical accounting policies affect the Company’s more significant judgments and estimates used in the preparation of these financial statements:
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2009 to 2013, remain open for possible review.
	Warrant Liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the Company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation, since the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 40,160,947 shares and 20,551,398 shares at March 31, 2015 and 2014, respectively.
	Recently Issued Accounting Standards – In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern.  This update requires management to assess the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are ready to be issued.  Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements.  This ASU is effective for annual periods beginning after December 15, 2016.  The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	In January 2015, the FASB issued ASU No. 2015-01, which eliminates the concept of extraordinary items for financial statement presentation purposes.  This ASU is effective for fiscal years beginning after December 15, 2015.  The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	3. Property and Equipment
	Property and equipment consist of the following:
		31-Mar-15			December 31, 2014
	Computers	$	60,834		$	59,076
	Research equipment		143,185			143,185
			204,019			202,261
	Accumulated depreciation		(161,589	)		(154,896	)
		$	42,430		$	47,365
	Depreciation expense was $6,693 and $12,634  for the three months ended March 31, 2015 and 2014, respectively.

RelatedParty_Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	4. Related-Party Transactions
	Cedars-Sinai Medical Center License Agreement
	Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of issued and pending U.S. and foreign patents and applications, and the term of the license will be until the last to expire of any patent claims that are issued covering this technology.
	As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Subsequently, the Company issued Cedars-Sinai an additional 100,000 shares of the Company’s common stock as an additional license fee.
	The Company has also entered into various sponsored research agreements with Cedars-Sinai and has paid an aggregate of approximately $1.2 million.  The last agreement concluded on March 19, 2014 at an incremental cost of $126,237.  As of March 31, 2015, Cedars-Sinai is not performing any research activities on behalf of the Company.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies
	Sponsored Research Agreements
	In an effort to expand the Company’s intellectual property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.
	ICON (formerly known as Aptiv Solutions)
	The Company has contracted with ICON to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010.  On September 17, 2013, the Company entered into a Master Services Agreement with ICON to provide certain services related to the Company’s products under development.  Simultaneously, the Company and ICON entered into Project Agreement Number 1 for the ICT-140 Phase II trial that provides for payments of approximately $2.7 million until completion of the services described therein.  On May 6, 2014, the Company and ICON entered into Amendment #1 to Project Agreement Number 1 to amend the project schedule and provide additional services for an additional fee of $170,004.  On August 21, 2014, the Company and ICON entered into Amendment #2 to Project Agreement Number 1 to amend the project schedule and replace the aggregate budget.  The total aggregate fee pursuant to the original agreement and the two modifications is $3.5 million. Currently, the Company has suspended development of ICT-140 and, therefore, there is no ongoing commitment related to this program.  On July 17, 2014, the Company and ICON entered into Project Agreement CD-133 for the ICT-121 Phase I trial that provides for payments of approximately $2.3 million until completion of the services described therein.
	As of March 31, 2015, the Company’s remaining obligation under the existing commitments is approximately $2.0 million.
	The Johns Hopkins University Licensing Agreement
	On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The Johns Hopkins University (JHU) under which it received an exclusive, worldwide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies. The Company is advancing a cancer vaccine program using JHU and other intellectual property according to commercially reasonable development timeline.  If successful and a product ultimately is registered, the Company will either sell the product directly or via a third-party partnership.
	Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee in the low hundreds of thousands of dollars, payable half in cash and half in shares of its common stock in two tranches, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. Annual minimum royalties or maintenance fees increase over time and range from low tens of thousands to low hundreds of thousands of dollars. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, totaling single digit millions of dollars if all milestones are met.  Royalties based on a low single digit percentage of net sales are also due on direct sales, while third party sublicensing payments will be shared at a low double digit percentage.
	The Company and JHU each have termination rights that include termination for any reason and for reasons relating to specific performance or financial conditions.   Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones.
	The University of Pittsburgh Patent License Agreement
	On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a worldwide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a worldwide non-exclusive license to the intellectual property for brain cancer.
	Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.
	In April 2015, the Company exercised its right to terminate this agreement effective October 12, 2015.
	Torrey Pines
	On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase IIb trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provided for the Company to pay an upfront fee and additional fees at the conclusion of the contract. On April 1, 2014, the Company and Torrey Pines entered into an Amended and Restated Contract Services Agreement for Torrey Pines to perform certain additional services in connection with the Company’s vaccine technologies.
	California Institute of Technology
	On September 9, 2014, the Company entered into an Exclusive License Agreement with the California Institute of Technology (Caltech) under which the Company acquired exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancers.
	Pursuant to the License Agreement, the Company agreed to pay a one time license fee, a minimum annual royalty based on a low single digit percentage of net revenues and an annual maintenance fee in the low tens of thousands of dollars.  In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones.
	Cedars-Sinai Medical Center
	In connection with the Cedars-Sinai Medical Center License Agreement and sponsored research agreement, the Company has certain commitments as described in Note 4.
	Manufacturing
	PharmaCell B.V.
	In March 2015, the Company entered into an Agreement for GMP Manufacturing of ICT-107  with PharmaCell B.V. (PharmaCell), pursuant to which PharmaCell will provide contract manufacturing services for the European production of ICT-107, a dendritic cell vaccine for the treatment of newly diagnosed glioblastoma multiforme.
	The Company will pay for manufacturing services performed by PharmaCell under the Agreement pursuant to statements of work entered into from time to time. The Company may unilaterally terminate the Agreement upon 90 days’ written notice to PharmaCell, or 30 days’ written notice in the event of a clinical hold or other suspension or early termination of a clinical trial. PharmaCell may terminate the Agreement in certain circumstances upon 90 days’ written notice to the Company. Either party may terminate the Agreement in the event of the other party’s insolvency or for the other party’s material breach of its obligations under the Agreement if such breach remains uncured after 30 days of receiving written notice of such breach. Absent early termination, the Agreement will continue until all services under applicable statements of work have been completed.
	Employment Agreements
	The Company has employment agreements with its management that provide for a base salary, bonus and stock option grants.  The aggregate annual base salary payable to this group is approximately $1.1 million and the potential bonus is approximately $400,000.  During the three months ended March 31, 2015, the Company issued an aggregate of 437,500 stock options to its management at a weighted average exercise price of $0.57 that vest over a period of 4 years.  Additionally, during the three months ended March 31, 2015, the Company issued 337,500 restricted shares of the Company’s common stock.  These shares will vest in March 2017.
	Operating Lease
	The Company entered into a lease for office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental increases by 3% on each anniversary date of the lease. Rent for the months of August and September 2013 was abated.  Rent expense was approximately $25,000 and $24,000 for the three months ended March 31, 2015 and 2014, respectively.
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2015		75,990
	2016		68,432
	Total	$	144,422

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Shareholders Equity	6. Shareholders’ Equity
	Underwritten Public Offering
	In February 2015, the Company raised approximately $14,500,000 (after commissions and offering expenses) from the sale of 26,650,000 shares of common stock and warrants to purchase 18,655,000 shares of common stock at an exercise price of $0.66 per share, to various investors in an underwritten public offering.  Each unit was priced at $0.60.  The warrants have a term of 60 months from the date of issuance.  The warrants also provide for a weighted-average adjustment to the exercise price if we issue or are deemed to issue additional shares of our common stock at a price per share less than the then effective price of the warrants, subject to certain exceptions (see “Warrant Liability” below.)
	Controlled Equity Offering
	On April 18, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement.  On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through March 31, 2015, we sold 6,949,261 shares of our common stock under the Sales Agreement that resulted in proceeds to the Company of approximately $9,402,383.  As of March 31, 2015, aggregate gross sales for additional common stock of approximately $7,081,494 remained available under the Sales Agreement.  No shares were sold during the three months ended March 31, 2015.
	Stock Options
	In February 2005, the Company adopted an Equity Incentive Plan (the Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. On September 20, 2013, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 12,000,000 shares. Options to purchase 4,339,340 common shares have been granted under the Plan and are outstanding as of March 31, 2015. Additionally, 260,000 shares of restricted common stock have been granted under the Plan.  As of March 31, 2015, there were 4,467,731 options available for issuance under the Plan.
	The following table summarizes stock option activity for the Company during the three months ended March 31, 2015:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Outstanding December 31, 2014	9,314,765			$	1.19			0		0
	Granted	1,193,000			$	0.58			0		0
	Exercised	0			$	0			0		0
	Forfeited or expired	(85,000	)		$	(2.25	)		0		0
	Outstanding March 31, 2015	10,422,765			$	1.24			3.52	$	11,000
	Vested or expected to vest at March 31, 2015	8,027,189			$	1.2			2.23	$	11,000
	As of March 31, 2015, the total unrecognized compensation cost related to unvested stock options amounted to $3.0 million, which will be recognized over the weighted-average remaining requisite service period of approximately  17 months.
	On March 20, 2015, the Company issued an aggregate of 260,000 shares of restricted common stock to certain members of management.  The shares will vest on March 19, 2017.  For accounting purposes, these shares were valued at $0.58, which was the stock price on the date of grant, and will be expensed over the service period of two years from the date of grant.
	Warrants
	In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50. The warrants have a five-year term from the date of issuance. As of March 31, 2015, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,609,898 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than the adjusted exercise price. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. During the quarter ended June 30, 2014, the exercise price was further adjusted to $1.85 and the number of warrants outstanding was increased to 2,854,196 to reflect the issuances pursuant to the Company’s Controlled Equity OfferingSM.  During the quarter ended September 30, 2014, the exercise price was further adjusted to $1.84 and the number of warrants outstanding was increased to 2,869,696 to reflect the issuances pursuant to the Company’s Controlled Equity OfferingSM.  During the quarter ended December 31, 2014, the exercise price was further adjusted to $1.79 and the number of warrants outstanding was increased to 2,949,845 to reflect the issuances pursuant to the Company’s Controlled Equity OfferingSM.  As a result of the February 2015 financing, the exercise price of the warrants was further adjusted to $1.44 and the number of warrants was proportionately increased to 3,666,836.  As of March 31, 2015, warrants to purchase 3,666,836 shares of the Company’s common stock remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of March 31, 2015, warrants to purchase 1,418,575 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of March 31, 2015, warrants to purchase 4,446,775 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the February 2015 underwritten public offering, the Company issued to the investors warrants to purchase 18,655,000 shares of the Company’s common stock at $0.66 per share.  The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than the adjusted exercise price.  Accordingly, these warrants do not qualify for equity treatment.  As of March 31, 2015, warrants to purchase 18,655,000 shares of the Company’s common stock remain outstanding relating to this public offering. (See “Warrant Liability” below.)
	Warrant Liability
	The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On March 31, 2015, the price per share of Company’s common stock was $0.49 per share compared to $0.73 per share at December 31, 2014.
	In connection with the sale of Preferred Stock in 2010, the Company issued to the investors warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three months ended March 31, 2014, the Company recorded a charge to other expense of $125,227. As of March 31, 2015, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 46 %; (iii) risk free rate of 0.05% and (iv) expected term of 0.09 years. For the three months ended March 31, 2015, the Company recorded a credit to other income of $7,746.  As of March 31, 2015, the carrying value of the warrant liability is $nil.
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. The Company recorded a charge to financing expense of $368,524 to reflect the issuance of the additional warrants. As of result of the Company’s Controlled Equity Offering during 2014, the exercise price of the warrants was adjusted to $ 1.79 and the number of warrants was proportionately increased to 2,949,867, net of exercises. The Company recorded a charge to financing expense of $62,683 to reflect the issuance of the additional warrants.  As of result of the Company’s February 2015 underwritten public offering, the exercise price of the warrants was adjusted to $ 1.44 and the number of warrants was proportionately increased to 3,666,836 . The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. For the three months ended March 31, 2014, the Company recorded a charge to other expense of $290,840.  As of March 31, 2015, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 74 %; (iii) risk free rate of 0.23.% and (iv) expected term of .89 years. For the three months ended March 31, 2015, the Company recorded a credit to other income of $634,910. As of March 31, 2015, the carrying value of the warrant liability is $44,002.
	In connection with the February 2015 underwritten public offering, the Company issued to the investors warrants to purchase 18,655,000 shares of the Company’s common stock at $0.66 per share.  The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $0.66.  Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability.The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 97.0%; (iii) risk free rate of 1.53% and (iv) expected term of 5 years.  Based upon these calculations, the Company calculated the initial valuation of the warrants to be $4,197,375.  As of March 31, 2015, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 92.0%; (iii) risk free rate of 1.34% and (iv) expected term of 4.86 years.  For the three months ended March 31, 2015, the Company recorded a credit to other income of $1,119,300. As of March 31, 2015, the carrying value of the warrant liability is $3,078,075.
	Volatility has been estimated using the historical volatility of the Company’s stock price.
	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended March 31, 2015 and 2014:
		31-Mar-15				31-Mar-14
	Balance – January 1	$	597,719			$	1,064,810
	Issuance of warrants and effect of repricing		4,286,314				0
	Exercise of warrants		0				0
	(Gain) or loss included in earnings		(1,761,956	)			416,067
	Transfers in and out/or out of Level 3		0				0
	Balance – March 31	$	3,122,077			$	1,480,877
	Additionally, during the three months ended March 31, 2015, the Company recorded a charge to financing expense of $88,939 to reflect the issuance of the additional warrants.

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	3 Months Ended
	Mar. 31, 2015
Compensation And Retirement Disclosure [Abstract]
401(k) Profit Sharing Plan	7. 401(k) Profit Sharing Plan
	During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the three months ended March 31, 2015 or March 31, 2014.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes
	Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.
	As of March 31, 2015, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with its deferred tax assets. Accordingly, a valuation allowance has been established for the full amount of the deferred tax assets.
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		31-Mar-15			31-Mar-14
	Income tax benefit at the federal statutory rate		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		-6	%		-6	%
	Change in fair value of warrant liability		124	%		5	%
	Change in valuation allowance for deferred tax assets		-84	%		35	%
	Total		0	%		0	%
		31-Mar-15			31-Mar-14
	Net operating loss carryforwards	$	17,060,834		$	16,900,628
	Stock-based compensation		2,315,228			2,094,628
	Less valuation allowance		(19,376,062	)		(18,995,256	)
	Net deferred tax asset	$	0		$	0
	As of March 31, 2015 and December 31, 2014, the Company had federal and California income tax net operating loss carry forwards of approximately $42.7 million and $40.8 million respectively. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.
	Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company had not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2012. The Company may incur limitations in the future if there is a change in ownership as computed under the prescribed method of the Internal Revenue Code.
	During the fourth quarter of 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and are offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Liquidity	Liquidity – As of March 31, 2015, the Company had working capital of $34,895,157, compared to working capital of $23,152,970 as of December 31, 2014. The estimated cost of completing the development of any of our current vaccine product candidates, including our stem cell immunotherapies, and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
Principles of Consolidation	Principles of Consolidation - The condensed consolidated balance sheets include the accounts of the Company and its subsidiaries. The consolidated statements of operations include the Company’s accounts and the accounts of its subsidiaries from the date of acquisition. All intercompany transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of March 31, 2015 and December 31, 2014, the Company had $33,431,067 and $10,427,810, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
Property and Equipment	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Costs	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
Stock Based Compensation	Stock Based Compensation – We have in effect an equity incentive plan under which stock options and awards have been granted to employees and non-employee members of the Board of Directors. We are required to estimate the fair value of share-based awards on the date of grant. The value of the award is principally recognized as expense ratably over the requisite service periods. We have estimated the fair value of stock options as of the date of grant using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. We evaluate the assumptions used to value stock options on a quarterly basis. The fair values generated by the Black-Scholes model may not be indicative of the actual fair values of our equity awards, as they do not consider other factors important to those awards to employees, such as continued employment and periodic vesting.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Three months			Three months
		Ended			Ended
		31-Mar-15			31-Mar-14
	Risk-free interest rate		1.87	%		2.23	%
	Expected dividend yield		None			None
	Expected life		7.1 Years			6.0Years
	Expected volatility		96.3	%		95.3	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the three months ended March 31, 2015 and 2014, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be zero.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises. As of March 31, 2015, the Company had 10,469,540 shares of authorized and unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
Income Taxes	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of March 31, 2015 and December 31, 2014, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of March 31, 2015, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2010 for the state and December 31, 2011 for the federal taxing authority.
	During 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represented a gain for U.S. tax purposes and were offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a larger portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.
Fair Value of Financial Instruments	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
Use of Estimates	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
Warrant Liability	Warrant Liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the Company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation, since the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 40,160,947 shares and 20,551,398 shares at March 31, 2015 and 2014, respectively.
Recently Issued Accounting Standards	Recently Issued Accounting Standards – In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern.  This update requires management to assess the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are ready to be issued.  Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements.  This ASU is effective for annual periods beginning after December 15, 2016.  The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	In January 2015, the FASB issued ASU No. 2015-01, which eliminates the concept of extraordinary items for financial statement presentation purposes.  This ASU is effective for fiscal years beginning after December 15, 2015.  The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
Critical Accounting Policies
Stock Based Compensation	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
Income Taxes	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2009 to 2013, remain open for possible review.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Stock Options Grants	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Three months			Three months
		Ended			Ended
		31-Mar-15			31-Mar-14
	Risk-free interest rate		1.87	%		2.23	%
	Expected dividend yield		None			None
	Expected life		7.1 Years			6.0Years
	Expected volatility		96.3	%		95.3	%
	Expected forfeitures		0	%		0	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment consist of the following:
		31-Mar-15			December 31, 2014
	Computers	$	60,834		$	59,076
	Research equipment		143,185			143,185
			204,019			202,261
	Accumulated depreciation		(161,589	)		(154,896	)
		$	42,430		$	47,365

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Rentals Under Operating Lease	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2015		75,990
	2016		68,432
	Total	$	144,422

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Stock Options Activity	The following table summarizes stock option activity for the Company during the three months ended March 31, 2015:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Outstanding December 31, 2014	9,314,765			$	1.19			0		0
	Granted	1,193,000			$	0.58			0		0
	Exercised	0			$	0			0		0
	Forfeited or expired	(85,000	)		$	(2.25	)		0		0
	Outstanding March 31, 2015	10,422,765			$	1.24			3.52	$	11,000
	Vested or expected to vest at March 31, 2015	8,027,189			$	1.2			2.23	$	11,000
Summary of Carrying Value of Warrant Liability	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended March 31, 2015 and 2014:
		31-Mar-15				31-Mar-14
	Balance – January 1	$	597,719			$	1,064,810
	Issuance of warrants and effect of repricing		4,286,314				0
	Exercise of warrants		0				0
	(Gain) or loss included in earnings		(1,761,956	)			416,067
	Transfers in and out/or out of Level 3		0				0
	Balance – March 31	$	3,122,077			$	1,480,877

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Federal Statutory Income Tax Rate to Loss before Income Taxes	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		31-Mar-15			31-Mar-14
	Income tax benefit at the federal statutory rate		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		-6	%		-6	%
	Change in fair value of warrant liability		124	%		5	%
	Change in valuation allowance for deferred tax assets		-84	%		35	%
	Total		0	%		0	%
Deferred Tax Asset
		31-Mar-15			31-Mar-14
	Net operating loss carryforwards	$	17,060,834		$	16,900,628
	Stock-based compensation		2,315,228			2,094,628
	Less valuation allowance		(19,376,062	)		(18,995,256	)
	Net deferred tax asset	$	0		$	0

Nature_of_Organization_Planned1

Nature of Organization (Planned Principal Operations Have Not Commenced) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Deficit accumulated during the development stage	($62,771,772)	($61,346,926)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Working capital	$34,895,157		$23,152,970
Certificates of deposit	33,431,067		10,427,810
Expected forfeitures	0.00%	0.00%
Shares authorized but unissued common stock	10,469,540
Tax benefit attributed to the stock-based compensation expense	0
Unrecognized Tax Benefits	0
Unrecognized Tax Benefits, liability, Penalties or Interest Accrued	0
Shares excluded from the computation of diluted net loss per share	40,160,947	20,551,398
Intellectual Property
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Fair value of intellectual property			$11,000,000
Computer Equipment
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	3 years
Minimum
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	3 years
Maximum
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Schedule of stock options grants
Risk-free interest rate	1.87%	2.23%
Expected dividend yield	0.00%	0.00%
Expected life	7 years 1 month 6 days	6 years
Expected volatility	96.30%	95.30%
Expected forfeitures	0.00%	0.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Components of Property and Equipment
Property and equipment, gross	$204,019	$202,261
Accumulated depreciation	-161,589	-154,896
Property and equipment, net	42,430	47,365
Computer Equipment
Components of Property and Equipment
Property and equipment, gross	60,834	59,076
Research Equipment
Components of Property and Equipment
Property and equipment, gross	$143,185	$143,185

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property Plant And Equipment [Abstract]
Depreciation expense	$6,693	$12,634

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended
	Mar. 19, 2014	Nov. 30, 2006	Mar. 31, 2015	Mar. 31, 2014
Related Party Transactions [Abstract]
Common stock, shares issued		694,000
Payment for upfront licensing fee		$62,000
Shares issued to related parties		100,000
Sponsored research agreement			1,998,619	1,699,760
Expected final contract price	$126,237

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended		1 Months Ended	0 Months Ended
	Mar. 20, 2015	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2015	6-May-14	Jul. 17, 2014	Sep. 17, 2013
Commitments And Contingencies [Line Items]
Nonrefundable And Noncreditable License And Maintenance Fee		12 months
Discretionary cash bonus		$0	$0
Options, Granted		1,193,000
Exercise option price		$0.58
Restricted shares issued by the company	260,000
Lease monthly rent		8,063
Operating lease rent expense		25,000	24,000
Subsequent Event
Commitments And Contingencies [Line Items]
License agreement termination date				12-Oct-15
ICON
Commitments And Contingencies [Line Items]
Estimated payments for services						2,300,000	2,700,000
Service fee, amendments and aggregate					170,004
Company's remaining commitment obligation		2,000,000
ICON | Amendment
Commitments And Contingencies [Line Items]
Estimated payments for services						3,500,000
JHU
Commitments And Contingencies [Line Items]
Period within effective date of License Agreement		30 days
PharmaCell B.V Agreement
Commitments And Contingencies [Line Items]
Written notice period for termination		90 days
Written notice period for early termination		30 days
Employment Agreement With Management
Commitments And Contingencies [Line Items]
Base salary		1,100,000
Discretionary cash bonus		$400,000
Options, Granted		437,500
Exercise option price		$0.57
Stock options, vesting period		4 years
Restricted shares issued by the company		337,500

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Rentals Under Operating Lease (Details) (USD $)	Mar. 31, 2015
Future Minimum Rentals Under the Operating Lease
2015	$75,990
2016	68,432
Operating lease obligation total	$144,422

Shareholders_Equity_Details_Te

Shareholders' Equity (Details Textual) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Mar. 20, 2015

Apr. 22, 2013

Apr. 18, 2013

Feb. 28, 2015

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2014

Mar. 31, 2014

Dec. 31, 2011

Dec. 31, 2010

Sep. 30, 2013

Oct. 24, 2011

Feb. 28, 2005

Class Of Stock [Line Items]

Proceeds from the common stock private placement

$14,500,000

Sale of common stock and warrants , shares

26,650,000

Purchase of common stock, shares

18,655,000

4,744,718

Common stock, price per share

$0.66

$1.41

$0.49

$0.73

Common stock and warrants issued for cash per share

$0.60

Common stock, $0.0001 par value; 149,000,000 shares authorized; 90,254,823 and 63,604,823 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively

9,025

6,360

6,360

Commission rate

3.00%

Listing of shares of common stock in connection with Sales Agreement

10,593,220

Common stock issued for cash, shares

0

Percentage of fair market value of common stock

not be less than 100%

Percentage of common stock voting rights held

more than 10%

Minimum percentage of fair market value of common stock

less than 110%

Maximum exercisable period of options

10 years

Maximum exercisable period of options if percentage of common stock voting rights held is more than ten percent

5 years

Common stock, shares authorized under the plan

12,000,000

8,000,000

6,000,000

Stock granted during period, Shares

260,000

Common stock, shares granted and outstanding

10,422,765

9,314,765

9,314,765

Stock options available for issuance

4,467,731

Unrecognized compensation cost related to unvested stock options

3,000,000

Weighted-average remaining requisite service period

P17M

Stock Issued During Period, Shares

260,000

Shares Issued, Price Per Share

$0.58

Common Stock Shares Purchased Private Placement Warrant

2,823,670

2,949,867

3,666,836

Warrants exercisable period after initial issuance

5 years

5 years

5 years

Number of warrants outstanding increased net of exercises

3,666,836

2,823,670

2,949,845

2,869,696

2,854,196

Adjusted exercise price of warrants

$1.44

$1.87

$1.87

$1.79

$1.84

$1.85

$1.79

Charge to financing expense

368,524

368,524

88,939

Initial valuation of warrants

2,476,790

Charge to financing expense

62,683

Valuation Allowances and Reserves, Deductions

4,197,375

Feb-11

Class Of Stock [Line Items]

Proceeds from the common stock private placement

2,476,790

Warrant liability carrying value

44,002

Charge to other expense

290,840

Other Income

634,910

February 2011 | Warranty Obligations

Class Of Stock [Line Items]

Purchase of common stock, shares

2,818,675

Common stock, price per share

2.25

February 2011 | Binomial Simulation | Previous Valuation Assumptions

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

146.00%

Risk-free interest rate

1.96%

Contractual life

5 years

February 2011 | Binomial Lattice Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

74.00%

Risk-free interest rate

0.23%

Contractual life

10 months 21 days

January

Class Of Stock [Line Items]

Common Stock Shares Purchased Private Placement Warrant

1,418,575

October

Class Of Stock [Line Items]

Purchase of common stock, shares

4,500,000

Common Stock Shares Purchased Private Placement Warrant

4,446,775

Warrants exercisable period after initial issuance

5 years

Feb-15

Class Of Stock [Line Items]

Purchase of common stock, shares

18,655,000

Common Stock Shares Purchased Private Placement Warrant

18,655,000

Warrants exercisable period after initial issuance

5 years

Exercise price of warrants

$0.66

Dividend yield rate

0.00%

0.00%

Expected volatility rate

97.00%

92.00%

Risk-free interest rate

1.53%

1.34%

Contractual life

5 years

4 years 10 months 10 days

Warrant liability carrying value

3,078,075

Other Income

1,119,300

Stock Compensation Plan

Class Of Stock [Line Items]

Common stock, shares granted and outstanding

4,339,340

Maximum | February 2011

Class Of Stock [Line Items]

Common stock, price per share

1.55

Minimum | February 2015

Class Of Stock [Line Items]

Common stock, price per share

$0.66

Cantor Fitzgerald And Company

Class Of Stock [Line Items]

Common stock issued for cash, shares

6,949,261

Proceeds from Issuance of common stock

9,402,383

Additional common stock sales gross

7,081,494

Cantor Fitzgerald And Company | Maximum

Class Of Stock [Line Items]

Common stock, $0.0001 par value; 149,000,000 shares authorized; 90,254,823 and 63,604,823 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively

25,000,000

Cantor Fitzgerald And Company | Offer and sale

Class Of Stock [Line Items]

Common stock, $0.0001 par value; 149,000,000 shares authorized; 90,254,823 and 63,604,823 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively

17,000,000

Warrant

Class Of Stock [Line Items]

Warrant exercise term investor relations agreement

60 months

Warrant | February 2011

Class Of Stock [Line Items]

Purchase of common stock, shares

2,609,898

Common stock, price per share

2.25

Warrant | February 2015

Class Of Stock [Line Items]

Purchase of common stock, shares

18,655,000

Common stock, price per share

$0.66

Preferred Stock

Class Of Stock [Line Items]

Proceeds from warrant shares attributed to free standing warrants related party of investor

5,710,500

Warrant liability carrying value

0

Preferred Stock | May

Class Of Stock [Line Items]

Purchase of common stock, shares

1,350,000

Common stock, price per share

2.5

$2.50

Common Stock Shares Purchased Private Placement Warrant

1,290,996

Preferred Stock | May | Binomial Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

102.00%

Risk-free interest rate

2.50%

Contractual life

60 months

Preferred Stock | May | Binomial Lattice Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Risk-free interest rate

0.05%

Contractual life

0 years

Charge to other expense

125,227

Change in fair value of warrant liability credited to other income

$7,746

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Summary of stock option activity
Options outstanding, Beginning Balance	9,314,765
Options, Granted	1,193,000
Options, Exercised	0
Options, Forfeited or expired	-85,000
Options outstanding, Ending Balance	10,422,765
Options, Vested or expected to vest	8,027,189
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.19
Exercise option price	$0.58
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Forfeited or expired	($2.25)
Weighted Average Exercise Price, Outstanding, Ending Balance	$1.24
Weighted Average Exercise Price, Vested or expected to vest	$1.20
Weighted Average Contractual Term, Outstanding	0 years
Weighted Average Contractual Term, Vested or expected to vest	0 years
Aggregate Intrinsic Value, Outstanding	$11,000
Aggregate Intrinsic Value, Vested or expected to vest	$11,000

Shareholders_Equity_Details_1

Shareholders' Equity (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Summary of carrying value of warrant liability
Beginning Balance, January 1	$597,719	$1,064,810
Issuance of warrants and effect of repricing	4,286,314	0
Exercise of warrants	0	0
(Gain) or loss included in earnings	-1,761,956	416,067
Transfers in and out/or out of Level 3	0	0
Ending Balance, March 31	$3,122,077	$1,480,877

401k_Profit_Sharing_Plan_Detai

401(k) Profit Sharing Plan (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Discretionary cash bonus	$0	$0

Income_Taxes_Details

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Federal statutory income tax rate to loss before income taxes
Income tax benefit at the federal statutory rate	-34.00%	-34.00%
State income tax benefit, net of federal tax benefit	-6.00%	-6.00%
Change in fair value of warrant liability	124.00%	5.00%
Change in valuation allowance for deferred tax assets	-84.00%	35.00%
Total	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Deferred Tax Asset
Net operating loss carryforwards	$17,060,834	$16,900,628
Stock-based compensation	2,315,228	2,094,628
Less valuation allowance	-19,376,062	-18,995,256
Net deferred tax asset	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Net operating losses expiration date	expire in 2022 and 2016
Intellectual Property
Income Taxes [Line Items]
Fair value of intellectual property		$11
Federal
Income Taxes [Line Items]
Income tax net operating loss carry forwards	42.7	40.8
California
Income Taxes [Line Items]
Income tax net operating loss carry forwards	42.7	$40.80